additionally proposed, but are not FDA requirements: Drotrecogin should only be ordered by a critical care specialist with experience weighing the risks and benefits of this medication. Drotrecogin should only be administered in a critical care area such as an Intensive Care Unit (ICU), or other unit with very frequent observation and monitoring. On October 25, 2011, Eli Lilly and Company announced a worldwide voluntary market withdrawal of Xigris [drotrecogin alfa (activated)]. In a recent study, Xigris failed to show a survival benefit for patients with severe sepsis and septic shock. Research The exact mechanism for this protein is currently not known, but efforts continue to isolate activated protein C mutants that lack anticoagulant properties for potential therapeutic use. References External links Information (PDF) on the drug from the Food and Drug Administration (FDA). Eli Lilly and Company brands Intensive care medicine Antithrombotic enzymes Withdrawn drugs